

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7070238

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Maura Murphy	08/04/2021
Matt Callahan	07/23/2021
RECEIVING PARTY DATA	
Name:	AFT PHARMACEUTICALS LIMITED
Street Address:	LEVEL 1, 129 HURSTMERE ROAD
Internal Address:	PO BOX 33-203
City:	TAKAPUNA, AUCKLAND
State/Country:	NEW ZEALAND
Postal Code:	0740
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17548877
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 368-2119
Email:	apsi@fr.com
Correspondent Name:	VASILY A. IGNATENKO
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	44422-0006002
NAME OF SUBMITTER:	MARY FLORCZAK
SIGNATURE:	/Mary Florczak/
DATE SIGNED:	12/13/2021
Total Attachments: 9	
source=Assignment-0006002#page1.tif	
source=Assignment-0006002#page2.tif	
source=Assignment-0006002#page3.tif	

source=Assignment-0006002#page4.tif

source=Assignment-0006002#page5.tif

source=Assignment-0006002#page6.tif

source=Assignment-0006002#page7.tif

source=Assignment-0006002#page8.tif

source=Assignment-0006002#page9.tif

ASSIGNMENT

For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, MAURA MURPHY, and MATT CALLAHAN, each individually assign to AFT PHARMACEUTICALS LIMITED, a corporation formed under the laws of NEW ZEALAND and having a principal place of business at Level 1, 129 Hurstmere Road, PO Box 33-203, Takapuna, Auckland 0740, NEW ZEALAND, and its successors, transferees, and assignees (collectively the "Assignee"), all of our individual and joint right, title, and interest throughout the world in the invention(s) (the "Subject Matter") described in a patent application that names us as inventors, is titled "PHARMACEUTICAL COMPOSITION CONTAINING ACETOMINOPHEN AND IBUPROFEN," and was filed in the United States Patent and Trademark Office on February 27, 2019, as application 16/287,836, and on February 27, 2020, as application PCT/US2020/020112 (the "Application").

This Assignment assigns, in addition to the Subject Matter, (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Applications and Granted Rights") in every country or region and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.

To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous assignment.

We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee's name.

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment.


We will communicate to the Assignee (or, at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter; will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents; and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

We were under obligation to make this Assignment on February 27, 2020, at least to the extent that this assignment does not confirm an earlier assignment.



Maura Murphy

Date: 8/4/21

Witnessed by:

Signature: 
Print Name: Alice Murphy

Date: 8/4/21

Signature: 
Print Name: Patrick Keenan

Date: 8/4/21

.....
Matt Callahan

Date:

Witnessed by:

Signature:

Date:

Print Name:

Signature:

Date:

Print Name:

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: AFT PHARMACEUTICALS LIMITED

Signature:

Date:

Name:

Title:

24139194.doc

ASSIGNMENT

For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, MAURA MURPHY, and MATT CALLAHAN, each individually assign to AFT PHARMACEUTICALS LIMITED, a corporation formed under the laws of NEW ZEALAND and having a principal place of business at Level 1, 129 Hurstmere Road, PO Box 33-203, Takapuna, Auckland 0740, NEW ZEALAND, and its successors, transferees, and assignees (collectively the "Assignee"), all of our individual and joint right, title, and interest throughout the world in the invention(s) (the "Subject Matter") described in a patent application that names us as inventors, is titled "PHARMACEUTICAL COMPOSITION CONTAINING ACETOMINOPHEN AND IBUPROFEN," and was filed in the United States Patent and Trademark Office on February 27, 2019, as application 16/287,836, and on February 27, 2020, as application PCT/US2020/020112 (the "Application").

This Assignment assigns, in addition to the Subject Matter, (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Applications and Granted Rights") in every country or region and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.

To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous assignment.

We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee's name.

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment.

We will communicate to the Assignee (or, at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter; will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents; and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

We were under obligation to make this Assignment on February 27, 2020, at least to the extent that this assignment does not confirm an earlier assignment.

Maura Murphy Date: _____


Witnessed by:

Signature: _____ Date: _____

Print Name: _____

Signature: _____ Date: _____

Print Name: _____



Matt Callahan

Date: 23 JULY '21

Witnessed by:

Signature: Bill Bosch

Date: 23 JULY 2021

Print Name: BILL BOSCH

Signature: Mary Beth Konetsky

Date: 23 July 2021

Print Name: Mary Beth Konetsky

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: AFT PHARMACEUTICALS LIMITED

Signature: _____

Date: _____

Name: _____

Title: _____

24139194.doc

ASSIGNMENT

For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, MAURA MURPHY, and MATT CALLAHAN, each individually assign to AFT PHARMACEUTICALS LIMITED, a corporation formed under the laws of NEW ZEALAND and having a principal place of business at Level 1, 129 Hurstmere Road, PO Box 33-203, Takapuna, Auckland 0740, NEW ZEALAND, and its successors, transferees, and assignees (collectively the “Assignee”), all of our individual and joint right, title, and interest throughout the world in the invention(s) (the “Subject Matter”) described in a patent application that names us as inventors, is titled “PHARMACEUTICAL COMPOSITION CONTAINING ACETOMINOPHEN AND IBUPROFEN,” and was filed in the United States Patent and Trademark Office on February 27, 2019, as application 16/287,836, and on February 27, 2020, as application PCT/US2020/020112 (the “Application”).

This Assignment assigns, in addition to the Subject Matter, (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors’ certificates for, any of the Subject Matter (collectively the “Applications and Granted Rights”) in every country or region and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee’s name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.

To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous assignment.

We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee’s name.

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment.

We will communicate to the Assignee (or, at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter; will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents; and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

We were under obligation to make this Assignment on February 27, 2020, at least to the extent that this assignment does not confirm an earlier assignment.

Maura Murphy Date: _____

Witnessed by:

Signature: _____ Date: _____

Print Name: _____

Signature: _____ Date: _____

Print Name: _____

Matt Callahan

Date: _____

Witnessed by:

Signature: _____

Date: _____

Print Name: _____

Signature: _____

Date: _____

Print Name: _____

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: AFT PHARMACEUTICALS LIMITED

Signature:  _____

Date: 28th July 2021 _____

Name: Hartley Atkinson _____

Title: Managing Director/CEO _____

24139194.doc